Neuroregeneration in neurodegenerative
Ana M Enciu1, Mihnea I Nicolescu1,2, Catalin G Manole1,2, Dafin F Mureşanu3, Laurenţiu M Popescu1,2and
Bogdan O Popescu2,4*
Background: Neuroregeneration is a relatively recent concept that includes neurogenesis, neuroplasticity, and
neurorestoration - implantation of viable cells as a therapeutical approach.
Discussion: Neurogenesis and neuroplasticity are impaired in brains of patients suffering from Alzheimer’s Disease
or Parkinson’s Disease and correlate with low endogenous protection, as a result of a diminished growth factors
expression. However, we hypothesize that the brain possesses, at least in early and medium stages of disease, a
“neuroregenerative reserve”, that could be exploited by growth factors or stem cells-neurorestoration therapies.
Summary: In this paper we review the current data regarding all three aspects of neuroregeneration in Alzheimer’s
Disease and Parkinson’s Disease.
Adult neuroregeneration is a complex concept, beyond
the common knowledge of neurogenesis that also com-
prises endogenous neuroprotection leading to neuro-
plasticity and neurorestoration -a therapeutical approach
of implantation of viable cells (Figure 1). Regeneration
in the central nervous system (CNS) implies that new
neurons, generated either through proliferation of endo-
genous stem/progenitor cells or by administration of
exogenous stem/precursor cells with potential to substi-
tute for lost tissue, will differentiate, survive, and inte-
grate into existing neural networks . Among the three
components of neuroregeneration previously mentioned,
neuroplasticity was the first one put forward, by Ramon
y Cajal, in 1894: “associations already established among
certain groups of cells would be notably reinforced by
means of the multiplication of the small terminal
branches of the dendritic appendages and axonal collat-
erals; but, in addition, completely new intercellular con-
nections could be established thanks to the new
formation of [axonal] collaterals and dendrites.” .
However, Ramon y Cajal discards, in the same paper,
the possibility of cell renewal: “it is known that the
nerve cells after the embryonic period have lost the
property of proliferation”. Adult neurogenesis was pro-
posed by Joseph Altman in the 1960’s, in a series of arti-
cles involving tritiated thymidine retaining cells in the
rat brain [3-5]. The newly emerged concept was a con-
troversy until the early 1990s, when several reports [6-9]
proved beyond doubt the existence of adult neural stem
The concepts of neuroplasticity and neural stem cells
led to the idea of neurorestoration as an alternative
therapy for neurodegenerative disorders such as Alzhei-
mer’s Disease (AD) and Parkinson’s Disease (PD), both
characterized by neuronal loss. Our review will attempt
to answer the question “Is there any neuroregeneration
in neurodegeneration?” taking into account the three
concepts mentioned above.
Neurogenesis in neurodegenerative diseases
The adult mammalian brain retains a limited capacity of
neurogenesis, which manifests in the subventricular
zone (SVZ) and subgranular zone of the hippocampal
dentate gyrus. The neuronal precursors migrate into the
olfactory bulb, the granular cell layer, or, if necessary, to
the striatum, CA1 region of hippocampus or cerebral
* Correspondence: email@example.com
2Laboratory of Molecular Medicine, ‘Victor Babeş’ National Institute of
Pathology, 99-101 Splaiul Independenţei, sector 5, Bucharest 050096,
Full list of author information is available at the end of the article
Enciu et al. BMC Neurology 2011, 11:75
© 2011 Enciu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Alzheimer’s Disease animal models
Neurogenesis in AD transgenic mice is usually impaired,
but the results may differ from one transgenic strain to
another . Haughey et al. reported that proliferation
and survival of neural precursor cells (NPC) was
reduced in the dentate gyrus of APP mutant mice with
already constituted amyloid deposits . Furthermore,
the decrement in NPC number was correlated with
accumulation of Ab, even in oligomeric, diffusible form
. Although Kolecki et al. confirmed the previous
results, they reported that overexpressing APP and Ab
in transgenic mice do not interfere with the mitotic
activity of NPC, as assessed by Ki-67 .
In vitro, Ab effects reported on mouse brain-derived
neurospheres are different with the type of peptide used:
i) Ab 25-35 induces neuronal differentiation and apop-
tosis in neural committed cells ; ii) Ab40 promotes
neurogenesis in NPCs ; iii) Ab42 stimulates neuro-
sphere formation and increases the number of neuronal
precursors ; it also has a reported effect of inducing
astrocytic differentiation .
Evidence of neurogenesis in AD human brain
An overexpression of neurogenesis markers (Doublecor-
tin - DCX, Polysialylated Neural Cell Adhesion Molecule
- PSA-NCAM and TUC-4) in hippocampus of AD
patients, without a correlated increase in mature neuro-
nal markers (NeuN, Calbinding D28k) is reported by Jin
et al. . This expression disjunction sustains the
hypothesis of AD as a failed attempt of precursor cells to
neuronal differentiation , but Boekhoorn et al argue
that DCX is a nonspecific marker, increased due to reac-
tive gliosis . Furthermore, Verwer et al. questioned
whether DCX+ cells are indeed neuroblasts, presenting
arguments for their astrocytic origin . Investigating
Musashi1 immunoreactivity in SVZ of AD patients, Ziab-
reva et al. also reported impaired neurogenesis, as com-
pared to controls . In turn, although Lovell et al.
isolated viable NSC from AD patients’ hippocampi, they
obtained decreased viable NPC yields and altered division
rates, as compared to controls .
In vitro studies using human neurospheres reported,
unlike in vitro models using rodent NPCs, that Ab 1-40
treatment impaired proliferation and differentiation of
precursor cells .
In order to assess neurogenesis in AD brain, adding to
contradictory results in literature, one must further take
into account the neurogenesis-stimulating effect of AD
Neurogenesis in PD animal models
Adult mice substantia nigra contains bromodeoxyuridine
(BrdU) incorporating cells that show dividing and differ-
entiating properties. In vivo, this potential seems to mate-
rialize into glial lineage, whereas in vitro, under
appropriate growth factors stimulation, neuronal pro-
genitors may be identified . Reports regarding neuro-
genesis in 6-hydroxydopamine (6-OHDA) models of PD
showed increased number of BrdU+ cells and a tendency
to migrate towards the lesioned striatal nuclei , but
without further differentiation on neural lineage .
Transgenic mice overexpressing human mutated a
synuclein exhibited reduced BrdU+ cells and decreased
survival of newly generated neurons, as compared to
aged-matched controls. Interestingly, the cessation of a
synuclein overexpression led to recovered neurogenesis
Neurogenesis in PD human brain
The numbers of proliferating cells in the subependymal
zone and neural precursor cells in the subgranular zone
and olfactory bulb are reduced in postmortem brains of
Parkinson’s Disease patients . However, there are
reports of newly generated neuroblasts PSA-NCAM + in
substantia nigra of PD patients, without a solid proof of
further dopaminergic neuronal differentiation or reinte-
gration in neuronal circuitry .
Endogenous neuroprotection and growth factors
Discovery of growth factors and their pro-survival effect
led to a closer investigation of specific nervous system
Figure 1 The large concept of neuroregeneration contains
three landmarks: endogenous protection by growth factors,
neurogenesis and neurorestoration. Rather than perceiving them
as isolated events, they should be viewed interrelated, one creating
the premises for generating the other.
Enciu et al. BMC Neurology 2011, 11:75
Page 2 of 7
cytokines - Nerve Growth Factor (NGF), Brain-Derived
Nerve Factor (BDNF), Glial-Derived Nerve Factor
(GDNF) - involvement in the outcome of neurodegen-
erative diseases. Interestingly, different neuronal subpo-
pulations require different growth factors to thrive, for
example NGF protects cholinergic neurons from various
insults , whereas for dopaminergic neurons, this
effect is better sustained by BDNF .
Neurotrophins (NGF, BDNF, neurotrophin 3 - NT3
and neurotrophin 4 - NT 4) are most studied for their
involvement in normal central nervous system (CNS)
development [33-36] and in normal  or pathological
ageing [38-40]. They exert their effect through tropo-
myosin-related kinase (Trk) receptors and activation of
several signaling cascades: i) IP3-DAG and subsequent
release of calcium, leading to synaptic plasticity; ii)
PI3K/Akt and transcription of prosurvival genes and iii)
MAPK/ERK and activation of differentiation promoting
substrates . With low affinity and also in immature
form (as proneurotrophins) they interact with p75NTR-
a tumor necrosis factor receptor which, in turn, upon
activation, leads to apoptosis in neuronal and non-neu-
ronal cells . Glial -Derived Neurotrophic Factor
(GDNF) is a growth factor from the transforming
growth factor b (TGFb) superfamily, with documented
neuroprotective effects in dopaminergic neurons cell
cultures , in vivo studies on laboratory animals 
and in animal models of PD [45,46]. It exerts its effects
through Ret receptor tyrosine kinase and GDNF family
receptor a1 (GFRa1) complex , although the role of
Ret signaling is controversial [48,49]. Mesencephalic
Astrocyte-Derived Neurotrophic Factor (MANF) and
Conserved Dopamine Neurotrophic Factor (CDNF) are
members of a novel, evolutionarily conserved neuro-
trophic factor family with specific protective properties
on dopaminergic neurons, as shown in 6-hydroxydopa-
mine (6-OHDA) animal models of PD . Further-
more, they seem to act more effectively than GDNF and
use a different protective mechanism .
Neurotrophins and growth factors in neurodegeneration
In both AD and PD human brains, levels of BDNF 
and its mRNA  are low. Furthermore, BDNF serum
levels correlate with AD severity . Correlated altera-
tion in TrkB expression in AD is also reported in corti-
cal neurons, but not in glial cells, which, surprisingly,
upregulate a truncated form of the receptor .
According to Tong et al., BDNF signaling pathway
seems also to be negatively affected in AD, by Ab 1-42
peptide interference with gene transcription. Treatment
of rat cortical neurons cultures with sublethal doses of
Ab peptide, interfered with the CREB activation-induced
transcription of the BDNF gene and suppressed BDNF-
induced activation of selective signaling pathways such
as Ras-MAPK/ERK and PI3-K/Akt .
The reports regarding NGF mRNA and protein levels
in AD brain are contradictory [57-59]. NGF deficiency
has been proposed as ethiopatogenic factor in sporadic
AD, and the AD11 anti-NGF mice recreate the pheno-
type and the functional impairment of early AD stages
. Also, in early stages, a loss of TrkA has been
reported , while Cuello et Bruno proposed the exis-
tence of a failure of the NGF maturation cascade in AD
. Ab load recreates the same NGF “dismetabolism”
in the hippocampus of laboratory rats, as proposed by
Cuello et al. . In vitro models showed Ab peptide as
a potent NGF -secretion stimulator in astrocytic rat cul-
tures and, in turn, NGF was shown to increase neuro-
toxic potency of amyloid peptide in primary rat
hippocampal cultures via p75 induction .
It is well documented that brains of PD patients
express lower GDNF levels  and growth factor deliv-
ery in brain of PD animal models exerts neuroprotective
effects and improves clinical outcome [65,66]. Further-
more, Sun et al. demonstrated in a rat model that
GDNF is more efficient than BDNF in protecting striatal
neurons from 6-hydroxydopamine (6-OHDA), compared
to the control group or BDNF group. Moreover, simul-
taneous administration of both growth factors showed
no benefit over GDNF treatment alone . However,
using vector-induced striatal neuron-restricted expres-
sion of both GDNF and BDNF genes, Cao et al.
reported an improved protein expression as to either
approach alone .
In human AD studies, there are controversial reports
of GDNF protein levels. Straten et al. reported higher
CSF concentration than age-matched controls along
with decreased serum concentration , whereas
Marksteiner’s et al. results showed increased plasma
levels in AD and mild cognitive impairment (MCI)
patients . However, in light of the serious side
effects reported after intracerebroventricular infusion of
GDNF in parkinsonian patients , attention was
drown toward MANF and CDNF, which will hopefully
make good candidates for novel therapies in PD.
Neuroplasticity in neurodegeneration
Neuroplasticity is a comprehensive term that illustrates
the brain’s capacity to adapt, structurally and function-
ally, to environmental enhancement. According to
Thickbroom and Mastaglia, the molecular mechanisms
underlying neuroplasticity are both neuronal and non-
neuronal and, furthermore, neuronal plasticity may be
synaptic or non-synaptic . Neuroplasticity is substrate
for learning and memory formation, cognitive abilities
progressively lost in AD and in late stages of PD.
Synaptic loss is one of the neurobiological hallmarks
of AD, from the first stages of the disease . The
synaptic dysfunction is apparently due to soluble Ab
Enciu et al. BMC Neurology 2011, 11:75
Page 3 of 7
oligomers, as proven by studies on human AD brains
 and AD animal models . Soluble Ab oligomers
have a proven inhibitory effect on NMDA-R - depen-
dent LTP , impairing even further the neuroplasti-
city, besides their roles in morphological and structural
degeneration of the synapse .
Synapse alteration is initially compensated by
“dynamic synaptic reorganization”, emphasized by a
paradoxical initial increase in synaptic markers . The
proof of network reorganization is sustained by studies
on AD brains showing increased polysialylated neural
cell adhesion molecule (PSA-NCAM) in dentate gyrus,
as compared to controls . Also investigating NCAM,
Jørgensen et al hypothesize that AD brain uses neuro-
plasticity as a compensatory measure for neuronal loss
. Furthermore, inflammatory environment - a con-
stant finding in AD brain - impairs neuronal plasticity
by inhibiting both (NMDA-R) - induced and voltage-
dependent calcium channel (VDCC)-induced LTP .
The other neuropathological hallmark of AD, tau hyper-
phosphorylation, correlates with low neuronal plasticity
and synaptic disorganization, as proven by studies on
hibernating animals . Possibly a protective mechanism
against neuronal apoptosis in unfavorable conditions, per-
sistent hyperphosphorylation will eventually lead to forma-
tion of paired helical filaments and cell destruction.
PD animal models also show impaired neuroplasticity.
Studies in mice overexpressing human a-synuclein
report both short-term and long-term altered presynap-
tic plasticity in the corticostriatal pathway . Trans-
genic mice bearing mutated a-synuclein - (A30P) a-
synuclein - also showed impaired short-time synaptic
plasticity  and the (6-OHDA) PD animal models
develop defective synaptic plasticity induction .
Morphological studies of idiopathic PD brains and PD
animal models reported that loss of dopaminergic input
on medium spiny neurons of striatum resulted in lower-
ment of dendritic length, dendritic spine density, and
total number of dendritic spines .
To conclude so far, there is evidence of impaired
neural plasticity in both AD  and PD  brains,
which occurs on various molecular levels, from growth
factors signaling to synaptic malfunction, disorganization
and cytoskeletal rearrangement. However, the brain pos-
sesses a latent recovery capacity and in early stages
some compensatory mechanisms are triggered (see
Table 1). Furthermore, the brain’s capacity to compen-
sate these structural and functional deficits is exploited
by neurorestoration attempts in animal models and
patients, as discussed below.
At the base of initial neurorestoration attempts lies the
idea of enhancing the endogenous neuroprotective effect
of growth factors in the CNS. At first, genetically modi-
fied fibroblasts to produce either BDNF, or NGF have
been transplanted in laboratory rats [88,89] and pri-
mates . The experiments were successful in rescuing
functional and cellular loss. The same type of experi-
ment was conducted, in 2005, on human patients, diag-
nosed with AD . The delivery system consisted of
induced pluripotent stem cells (iPS), generated from the
recipient’s fibroblast population and genetically modified
into secreting NGF. The authors reported significant
progress at 22 months follow-up, quantified by cognitive
scales and PET -Scan.
For PD patients, there are reports since the 1980’s of
fetal midbrain dopamine cells implants . The clinical
Table 1 Evidences of impaired neuroregeneration in AD and PD
Evidence of impairment Evidence of compensatory mechanism
Neurogenesis AD Decreased number of NPCs and altered division rates Increased neuroproliferation markers 
PD Reduced number of NPCs  Increased number of PSA-NCAM + cells 
Neuroprotection AD Low BDNF mRNA and protein levels 
Controversed data on NGF levels [40,48,49]
Upregulation of glial truncated TrkB 
Possibly upregulation of NGF with ageing and
Ab stimulates NGF astrocytic secrection 
High GDNF levels in cerebrospinal fluid
PD Low BDNF mRNA and protein levels  BDNF pretreatment protects dopaminergic neurons
Low GDNF protein levels 
Neuroplasticity AD Synaptic loss 
LTP impairment by Abeta oligomers and inflammatory
“Dynamic synaptic reorganization” .
NCAM increase in dentate gyrus 
PD Loss of dendritic spines following loss of dopaminergic input 
Impaired synaptic plasticity in several models of PD [87-89]
Enciu et al. BMC Neurology 2011, 11:75
Page 4 of 7
outcome was improved [93,94] and engraftment of trans-
planted cells was successful [95,96], although some
authors questioned the utility of the procedure in older
patients . However, two double-blinded, randomized,
controlled trials set back the initial positivism, showing
cell transplantation to be less effective than deep brain sti-
mulation , in preventing recurrent dyskinesia. It seems
however, that reported improvement is due to replace-
ment by graft cells of aged brain cells , rather than sti-
mulation of the brain’s own neurorestorative mechanism.
Other restorative models, tested in vitro or in animal
models of AD and PD, use stem cells therapy: i) embryo-
nic stem cells ; ii) embryonic stem cells-derived neu-
rospheres ; iii) transdifferentiated stem cells (stem
cells forced to differentiate outside their lineage by special
growth media and specific stimuli) (e.g. hematopoietic
stem cells), or iv) mesenchimal stem cells induced into
secreting increased quantities of growth factors .
Apel et al. report neuroprotective effects of dental pulp
cells co-cultured with hippocampal and mesencephalic rat
neurons, in in vitro AD and PD models . Murell et al
used human olfactory mucosa-derived neuronal progeni-
tors to obtain dopaminergic neurons and transplant them
in a rat PD model brain. The outcome was favorable and
no difference was noted between transplants received
form healthy donors or from Parkinson patients .
As expected, most reports incline towards progressive
impairment of neuroregeneration resources in AD and
PD brains, as proven on human post-mortem analysis,
animal models and in vitro studies. However, due to
increased amount of evidence that proper stimulation or
supply of growth factors restores some of the cognitive
loss and ameliorates behavioral skills, we hypothesize
that the brain possess, at least in early and medium stages
of disease, a “neuroregenerative reserve”, that may be and
begins to be, targeted as a therapeutical perspective.
List of abbreviations
AD: Alzheimer’s Disease; PD: Parkinson’s Disease; NPCs: neural precursor cells;
PSA-NCAM: Polysialylated Neural Cell Adhesion Molecule; BDNF: Brain
Derived Nerve Factor; TrkB: tropomyosin-related kinase receptor B; NGF:
Nerve Growth Factor; GDNF: Glial Derived Nerve Factor
This paper is supported by the Sectorial Operational Programme Human
Resources Development (SOP HRD), financed from the European Social Fund
and by the Romanian Government under the contract number POSDRU/89/
1.5/S/64109 and by the Executive Unit for Financing Higher Education,
Research, Development and Innovation - Romania (UEFISCDI), Program 4
(Partnerships in Priority Domains), grant nr. 41-013/2007.
1Department of Cellular and Molecular Medicine, ‘Carol Davila’ University of
Medicine and Pharmacy, School of Medicine, 8 Eroilor Sanitari, sector 5,
Bucharest 050474, Romania.2Laboratory of Molecular Medicine, ‘Victor Babeş’
National Institute of Pathology, 99-101 Splaiul Independenţei, sector 5,
Bucharest 050096, Romania.3Department of Neurology, ‘Iuliu Hatieganu’
University of Medicine and Pharmacy, 8, Victor Babeş, Cluj Napoca 400023,
Romania.4Department of Neurology, University Hospital Bucharest, ‘Carol
Davila’ University of Medicine and Pharmacy, 169 Splaiul Independenţei,
sector 5, Bucharest 050098, Romania.
All authors contributed equally to elaboration of the manuscript, read and
approved the final manuscript.
The authors declare that they have no competing interests.
Received: 5 March 2011 Accepted: 23 June 2011
Published: 23 June 2011
1. Johansson BB: Regeneration and plasticity in the brain and spinal cord. J
Cereb Blood Flow Metab 2007, 27:1417-1430.
2. Ramon y Cajal S: The Croonian lecture: La fine structure des centres
nerveux. Proc Roy Soc London 1894, 55:444-467.
3.Altman J: Autoradiographic study of degenerative and regenerative
proliferation of neuroglia cells with tritiated thymidine. Exp Neurol 1962,
4. Altman J: Are new neurons formed in the brains of adult mammals?
Science 1962, 135:1127-1128.
5. Altman J, Das GD: Autoradiographic and histological evidence of postnatal
hippocampal neurogenesis in rats. J Comp Neurol 1965, 124:319-335.
6. McKay R: Stem cells in the central nervous system. Science 1997,
7.Morshead CM, Reynolds BA, Craig CG, McBurney MW, Staines WA,
Morassutti D, Weiss S, van der Kooy D: Neural stem cells in the adult
mammalian forebrain: a relatively quiescent subpopulation of
subependymal cells. Neuron 1994, 13:1071-1082.
8. Reynolds BA, Weiss S: Generation of neurons and astrocytes from
isolated cells of the adult mammalian central nervous system. Science
9.Shihabuddin LS, Palmer TD, Gage FH: The search for neural progenitor
cells: prospects for the therapy of neurodegenerative disease. Mol Med
Today 1999, 5:474-480.
10. Lee E, Son H: Adult hippocampal neurogenesis and related neurotrophic
factors. BMB Rep 2009, 42:239-244.
11. Chuang TT: Neurogenesis in mouse models of Alzheimer’s disease.
Biochim Biophys Acta 2010.
12.Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP:
Disruption of neurogenesis by amyloid beta-peptide, and perturbed
neural progenitor cell homeostasis, in models of Alzheimer’s disease. J
Neurochem 2002, 83:1509-1524.
13.Kolecki R, Lafauci G, Rubenstein R, Mazur-Kolecka B, Kaczmarski W,
Frackowiak J: The effect of amyloidosis-beta and ageing on
proliferation of neuronal progenitor cells in APP-transgenic
mouse hippocampus and in culture. Acta Neuropathol 2008,
14. Calafiore M, Battaglia G, Zappala A, Trovato-Salinaro E, Caraci F, Caruso M,
Vancheri C, Sortino MA, Nicoletti F, Copani A: Progenitor cells from the
adult mouse brain acquire a neuronal phenotype in response to beta-
amyloid. Neurobiol Aging 2006, 27:606-613.
15.Chen Y, Dong C: Abeta40 promotes neuronal cell fate in neural
progenitor cells. Cell Death Differ 2009, 16:386-394.
16.Sotthibundhu A, Li QX, Thangnipon W, Coulson EJ: Abeta(1-42) stimulates
adult SVZ neurogenesis through the p75 neurotrophin receptor.
Neurobiol Aging 2009, 30:1975-1985.
17. Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA:
Increased hippocampal neurogenesis in Alzheimer’s disease. Proc Natl
Acad Sci USA 2004, 101:343-347.
18. Li B, Yamamori H, Tatebayashi Y, Shafit-Zagardo B, Tanimukai H, Chen S,
Iqbal K, Grundke-Iqbal I: Failure of neuronal maturation in Alzheimer
disease dentate gyrus. J Neuropathol Exp Neurol 2008, 67:78-84.
19. Boekhoorn K, Joels M, Lucassen PJ: Increased proliferation reflects glial
and vascular-associated changes, but not neurogenesis in the presenile
Alzheimer hippocampus. Neurobiol Dis 2006, 24:1-14.
Enciu et al. BMC Neurology 2011, 11:75
Page 5 of 7
20. Verwer RW, Sluiter AA, Balesar RA, Baayen JC, Noske DP, Dirven CM,
Wouda J, van Dam AM, Lucassen PJ, Swaab DF: Mature astrocytes in the
adult human neocortex express the early neuronal marker doublecortin.
Brain 2007, 130:3321-3335.
Ziabreva I, Perry E, Perry R, Minger SL, Ekonomou A, Przyborski S, Ballard C: Altered
neurogenesis in Alzheimer’s disease. J Psychosom Res 2006, 61:311-316.
Lovell MA, Geiger H, Van Zant GE, Lynn BC, Markesbery WR: Isolation of
neural precursor cells from Alzheimer’s disease and aged control
postmortem brain. Neurobiol Aging 2006, 27:909-917.
Mazur-Kolecka B, Golabek A, Nowicki K, Flory M, Frackowiak J: Amyloid-beta
impairs development of neuronal progenitor cells by oxidative
mechanisms. Neurobiol Aging 2006, 27:1181-1192.
Waldau B, Shetty AK: Behavior of neural stem cells in the Alzheimer
brain. Cell Mol Life Sci 2008, 65:2372-2384.
Lie DC, Dziewczapolski G, Willhoite AR, Kaspar BK, Shults CW, Gage FH: The
adult substantia nigra contains progenitor cells with neurogenic
potential. J Neurosci 2002, 22:6639-6649.
Liu BF, Gao EJ, Zeng XZ, Ji M, Cai Q, Lu Q, Yang H, Xu QY: Proliferation of
neural precursors in the subventricular zone after chemical lesions of
the nigrostriatal pathway in rat brain. Brain Res 2006, 1106:30-39.
Aponso PM, Faull RL, Connor B: Increased progenitor cell proliferation
and astrogenesis in the partial progressive 6-hydroxydopamine model
of Parkinson’s disease. Neuroscience 2008, 151:1142-1153.
Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Horsten S, Schmidt T,
Boy J, Kuhn M, Nguyen HP, Teismann P, Schulz JB, Neumann M, Pichler BJ,
Reischl G, Holzmann C, Schmitt I, Bornemann A, Kuhn W, Zimmermann F,
Servadio A, Riess O: Neurodegeneration and motor dysfunction in a
conditional model of Parkinson’s disease. J Neurosci 2008, 28:2471-2484.
Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I,
Hirsch EC: Dopamine depletion impairs precursor cell proliferation in
Parkinson disease. Nat Neurosci 2004, 7:726-735.
Borta A, Hoglinger GU: Dopamine and adult neurogenesis. J Neurochem
Auld DS, Mennicken F, Quirion R: Nerve growth factor rapidly induces
prolonged acetylcholine release from cultured basal forebrain neurons:
differentiation between neuromodulatory and neurotrophic influences. J
Neurosci 2001, 21:3375-3382.
Baquet ZC, Bickford PC, Jones KR: Brain-derived neurotrophic factor is required
for the establishment of the proper number of dopaminergic neurons in the
substantia nigra pars compacta. J Neurosci 2005, 25:6251-6259.
Klein R: Role of neurotrophins in mouse neuronal development. FASEB J
Davies AM, Minichiello L, Klein R: Developmental changes in NT3 signalling
via TrkA and TrkB in embryonic neurons. EMBO J 1995, 14:4482-4489.
Conover JC, Yancopoulos GD: Neurotrophin regulation of the developing
nervous system: analyses of knockout mice. Rev Neurosci 1997, 8:13-27.
Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S: Brain-derived
neurotrophic factor and the development of structural neuronal
connectivity. Dev Neurobiol 70:271-288.
Mattson MP: Neuroprotective signaling and the aging brain: take away
my food and let me run. Brain Res 2000, 886:47-53.
Cole GM, Frautschy SA: The role of insulin and neurotrophic factor
signaling in brain aging and Alzheimer’s Disease. Exp Gerontol 2007,
Peterson AL, Nutt JG: Treatment of Parkinson’s disease with trophic
factors. Neurotherapeutics 2008, 5:270-280.
Lanni C, Stanga S, Racchi M, Govoni S: The expanding universe of
neurotrophic factors: therapeutic potential in aging and age-associated
disorders. Curr Pharm Des 16:698-717.
Reichardt LF: Neurotrophin-regulated signalling pathways. Philos Trans R
Soc Lond B Biol Sci 2006, 361:1545-1564.
Volosin M, Song W, Almeida RD, Kaplan DR, Hempstead BL, Friedman WJ:
Interaction of survival and death signaling in basal forebrain neurons: roles
of neurotrophins and proneurotrophins. J Neurosci 2006, 26:7756-7766.
Piltonen M, Bespalov MM, Ervasti D, Matilainen T, Sidorova YA, Rauvala H,
Saarma M, Mannisto PT: Heparin-binding determinants of GDNF reduce
its tissue distribution but are beneficial for the protection of nigral
dopaminergic neurons. Exp Neurol 2009, 219:499-506.
Oo TF, Kholodilov N, Burke RE: Regulation of natural cell death in
dopaminergic neurons of the substantia nigra by striatal glial cell line-
derived neurotrophic factor in vivo. J Neurosci 2003, 23:5141-5148.
45. Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, Horellou P:
Intrastriatal injection of an adenoviral vector expressing glial-cell-line-
derived neurotrophic factor prevents dopaminergic neuron
degeneration and behavioral impairment in a rat model of Parkinson
disease. Proc Natl Acad Sci USA 1997, 94:8818-8823.
Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C,
Mandel RJ, Annett L, Kirik D: Continuous low-level glial cell line-derived
neurotrophic factor delivery using recombinant adeno-associated viral
vectors provides neuroprotection and induces behavioral recovery in a
primate model of Parkinson’s disease. J Neurosci 2005, 25:769-777.
Sariola H, Saarma M: Novel functions and signalling pathways for GDNF. J
Cell Sci 2003, 116:3855-3862.
Jain S, Golden JP, Wozniak D, Pehek E, Johnson EM Jr, Milbrandt J: RET is
dispensable for maintenance of midbrain dopaminergic neurons in
adult mice. J Neurosci 2006, 26:11230-11238.
Kramer ER, Aron L, Ramakers GM, Seitz S, Zhuang X, Beyer K, Smidt MP,
Klein R: Absence of Ret signaling in mice causes progressive and late
degeneration of the nigrostriatal system. PLoS Biol 2007, 5:e39.
Voutilainen MH, Back S, Porsti E, Toppinen L, Lindgren L, Lindholm P,
Peranen J, Saarma M, Tuominen RK: Mesencephalic astrocyte-derived
neurotrophic factor is neurorestorative in rat model of Parkinson’s
disease. J Neurosci 2009, 29:9651-9659.
Lindholm P, Voutilainen MH, Lauren J, Peranen J, Leppanen VM,
Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T,
Tuominen RK, Saarma M: Novel neurotrophic factor CDNF protects and
rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
Mattson MP: Glutamate and neurotrophic factors in neuronal plasticity
and disease. Ann N Y Acad Sci 2008, 1144:97-112.
Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S: New insights into brain
BDNF function in normal aging and Alzheimer disease. Brain Res Rev
Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M,
Buchkremer G, Schott K: Stage-dependent BDNF serum concentrations in
Alzheimer’s disease. J Neural Transm 2006, 113:1217-1224.
Schindowski K, Belarbi K, Buee L: Neurotrophic factors in Alzheimer’s
disease: role of axonal transport. Genes Brain Behav 2008, 7(Suppl 1):43-56.
Tong L, Balazs R, Thornton PL, Cotman CW: Beta-amyloid peptide at
sublethal concentrations downregulates brain-derived neurotrophic
factor functions in cultured cortical neurons. J Neurosci 2004,
Hefti F: Development of effective therapy for Alzheimer’s disease based
on neurotrophic factors. Neurobiol Aging 1994, 15(Suppl 2):S193-194.
Mufson EJ, Ikonomovic MD, Styren SD, Counts SE, Wuu J, Leurgans S,
Bennett DA, Cochran EJ, DeKosky ST: Preservation of brain nerve growth
factor in mild cognitive impairment and Alzheimer disease. Arch Neurol
O’Bryant SE, Hobson V, Hall JR, Waring SC, Chan W, Massman P, Lacritz L,
Cullum CM, Diaz-Arrastia R: Brain-derived neurotrophic factor levels in
Alzheimer’s disease. J Alzheimers Dis 2009, 17:337-341.
Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ:
Reduction of cortical TrkA but not p75(NTR) protein in early-stage
Alzheimer’s disease. Ann Neurol 2004, 56:520-531.
Cuello AC, Bruno MA: The failure in NGF maturation and its increased
degradation as the probable cause for the vulnerability of cholinergic
neurons in Alzheimer’s disease. Neurochem Res 2007, 32:1041-1045.
Cuello AC, Bruno MA, Allard S, Leon W, Iulita MF: Cholinergic involvement
in Alzheimer’s disease. A link with NGF maturation and degradation. J
Mol Neurosci 2010, 40:230-235.
Schulte-Herbruggen O, Hamker U, Meske V, Danker-Hopfe H, Ohm TG,
Hellweg R: Beta/A4-Amyloid increases nerve growth factor production in
rat primary hippocampal astrocyte cultures. Int J Dev Neurosci 2007,
Chauhan NB, Siegel GJ, Lee JM: Depletion of glial cell line-derived
neurotrophic factor in substantia nigra neurons of Parkinson’s disease
brain. J Chem Neuroanat 2001, 21:277-288.
Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, Forsayeth J,
Bankiewicz KS: Functional effects of AAV2-GDNF on the dopaminergic
nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther
Ericson C, Georgievska B, Lundberg C: Ex vivo gene delivery of GDNF
using primary astrocytes transduced with a lentiviral vector provides
Enciu et al. BMC Neurology 2011, 11:75
Page 6 of 7
neuroprotection in a rat model of Parkinson’s disease. Eur J Neurosci Download full-text
Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI: Comparison of the
capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a
rat model of Parkinson’s disease. Brain Res 2005, 1052:119-129.
Cao H, Zhang GR, Wang X, Kong L, Geller AI: Enhanced nigrostriatal
neuron-specific, long-term expression by using neural-specific promoters
in combination with targeted gene transfer by modified helper virus-
free HSV-1 vector particles. BMC Neurosci 2008, 9:37.
Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T: Glial cell-line
derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid
and serum of patients with early Alzheimer’s disease and normal
controls. J Alzheimers Dis 2009, 18:331-337.
Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechteriakov S,
Oberbauer H, Auffinger S, Hinterholzl J, Hinterhuber H, Humpel C: Five out
of 16 plasma signaling proteins are enhanced in plasma of patients with
mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 2009.
Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr,
Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF: Randomized,
double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in
PD. Neurology 2003, 60:69-73.
Thickbroom GW, Mastaglia FL: Plasticity in neurological disorders and
challenges for noninvasive brain stimulation (NBS). J Neuroeng Rehabil
Arendt T: Synaptic degeneration in Alzheimer’s disease. Acta Neuropathol
Walsh DM, Selkoe DJ: Deciphering the molecular basis of memory failure
in Alzheimer’s disease. Neuron 2004, 44:181-193.
Rowan MJ, Klyubin I, Cullen WK, Anwyl R: Synaptic plasticity in animal
models of early Alzheimer’s disease. Philos Trans R Soc Lond B Biol Sci
Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M,
Viola KL, Klein WL: Abeta oligomer-induced aberrations in synapse
composition, shape, and density provide a molecular basis for loss of
connectivity in Alzheimer’s disease. J Neurosci 2007, 27:796-807.
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA,
Klein WL: Alzheimer’s disease-affected brain: presence of oligomeric A
beta ligands (ADDLs) suggests a molecular basis for reversible memory
loss. Proc Natl Acad Sci USA 2003, 100:10417-10422.
Arendt T, Bruckner MK: Linking cell-cycle dysfunction in Alzheimer’s
disease to a failure of synaptic plasticity. Biochim Biophys Acta 2007,
Mikkonen M, Soininen H, Tapiola T, Alafuzoff I, Miettinen R: Hippocampal
plasticity in Alzheimer’s disease: changes in highly polysialylated NCAM
immunoreactivity in the hippocampal formation. Eur J Neurosci 1999,
Jorgensen OS, Brooksbank BW, Balazs R: Neuronal plasticity and astrocytic
reaction in Down syndrome and Alzheimer disease. J Neurol Sci 1990,
Min SS, Quan HY, Ma J, Han JS, Jeon BH, Seol GH: Chronic brain
inflammation impairs two forms of long-term potentiation in the rat
hippocampal CA1 area. Neurosci Lett 2009, 456:20-24.
Arendt T, Stieler J, Strijkstra AM, Hut RA, Rudiger J, Van der Zee EA,
Harkany T, Holzer M, Hartig W: Reversible paired helical filament-like
phosphorylation of tau is an adaptive process associated with neuronal
plasticity in hibernating animals. J Neurosci 2003, 23:6972-6981.
Watson JB, Hatami A, David H, Masliah E, Roberts K, Evans CE, Levine MS:
Alterations in corticostriatal synaptic plasticity in mice overexpressing
human alpha-synuclein. Neuroscience 2009, 159:501-513.
Steidl JV, Gomez-Isla T, Mariash A, Ashe KH, Boland LM: Altered short-term
hippocampal synaptic plasticity in mutant alpha-synuclein transgenic
mice. Neuroreport 2003, 14:219-223.
Picconi B, Ghiglieri V, Bagetta V, Barone I, Sgobio C, Calabresi P: Striatal
synaptic changes in experimental parkinsonism: role of NMDA receptor
trafficking in PSD. Parkinsonism Relat Disord 2008, 14(Suppl 2):S145-149.
Deutch AY, Colbran RJ, Winder DJ: Striatal plasticity and medium spiny
neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord
2007, 13(Suppl 3):S251-258.
Mufson EJ, Kordower JH: Cortical neurons express nerve growth factor
receptors in advanced age and Alzheimer disease. Proc Natl Acad Sci USA
88.Chen KS, Gage FH: Somatic gene transfer of NGF to the aged brain:
behavioral and morphological amelioration. J Neurosci 1995,
Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O:
Implanted fibroblasts genetically engineered to produce brain-derived
neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to
dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994,
Smith DE, Roberts J, Gage FH, Tuszynski MH: Age-associated neuronal
atrophy occurs in the primate brain and is reversible by growth factor
gene therapy. Proc Natl Acad Sci USA 1999, 96:10893-10898.
Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A,
Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ,
Kordower JH, Gall C, Conner J: A phase 1 clinical trial of nerve growth
factor gene therapy for Alzheimer disease. Nat Med 2005, 11:551-555.
Bradford HF: The use of foetal human brain tissue as brain implants:
phenotype manipulation by genetic manipulation and biochemical
induction. Keio J Med 2002, 51:148-153.
Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, Villafane G,
Jeny R, Samson Y, Keravel Y, Gaston A, Degos JD, Peschanski M, Cesaro P,
Nguyen JP: Long-term outcome of unilaterally transplanted parkinsonian
patients. I. Clinical approach. Brain 1996, 119(Pt 1):41-50.
Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH,
Olanow CW: Long-term evaluation of bilateral fetal nigral transplantation
in Parkinson disease. Arch Neurol 1999, 56:179-187.
Mendez I, Sanchez-Pernaute R, Cooper O, Vinuela A, Ferrari D, Bjorklund L,
Dagher A, Isacson O: Cell type analysis of functional fetal dopamine cell
suspension transplants in the striatum and substantia nigra of patients
with Parkinson’s disease. Brain 2005, 128:1498-1510.
Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H,
Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O: Dopamine
neurons implanted into people with Parkinson’s disease survive without
pathology for 14 years. Nat Med 2008, 14:507-509.
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S,
Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S: Transplantation
of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J
Med 2001, 344:710-719.
Geraerts M, Krylyshkina O, Debyser Z, Baekelandt V: Concise review:
therapeutic strategies for Parkinson disease based on the modulation of
adult neurogenesis. Stem Cells 2007, 25:263-270.
Barzilay R, Levy YS, Melamed E, Offen D: Adult stem cells for neuronal
repair. Isr Med Assoc J 2006, 8:61-66.
100. Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY,
McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O:
Embryonic stem cells develop into functional dopaminergic neurons
after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA
101. Wang Q, Matsumoto Y, Shindo T, Miyake K, Shindo A, Kawanishi M,
Kawai N, Tamiya T, Nagao S: Neural stem cells transplantation in cortex in
a mouse model of Alzheimer’s disease. J Med Invest 2006, 53:61-69.
102. Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D: Adult neurotrophic
factor-secreting stem cells: a potential novel therapy for
neurodegenerative diseases. Isr Med Assoc J 2009, 11:201-204.
103. Apel C, Forlenza OV, de Paula VJ, Talib LL, Denecke B, Eduardo CP,
Gattaz WF: The neuroprotective effect of dental pulp cells in models of
Alzheimer’s and Parkinson’s disease. J Neural Transm 2009, 116:71-78.
104. Murrell W, Wetzig A, Donnellan M, Feron F, Burne T, Meedeniya A, Kesby J,
Bianco J, Perry C, Silburn P, Mackay-Sim A: Olfactory mucosa is a potential
source for autologous stem cell therapy for Parkinson’s disease. Stem
Cells 2008, 26:2183-2192.
The pre-publication history for this paper can be accessed here:
Cite this article as: Enciu et al.: Neuroregeneration in neurodegenerative
disorders. BMC Neurology 2011 11:75.
Enciu et al. BMC Neurology 2011, 11:75
Page 7 of 7